Overview

Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
Tigecycline is being developed as an agent that overcomes tetracycline-resistance mechanisms and provides activity against emerging multi-drug resistant pathogens. The purpose of this protocol is to determine the linkage between time related clinical measures of infection response and time to bacterial eradication in patients with intravascular catheter infections caused by Staphylococcus epidermidis and other coagulase negative staphylococci.
Phase:
Phase 4
Details
Lead Sponsor:
CPL Associates
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Minocycline
Tigecycline